Drugs / CGC738
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06870279 | May 2025 → Aug 2026 overdue | clear cell renal carcinoma | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06728189 | Nov 2024 → Oct 2026 expected | cancer | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGC738 | “evaluate the efficacy, safety and PK of CGC738 in the treatment of advanced malignant solid tumors.” NCT06728189 ↗ |
| Modality | Cell therapy | “Biological: CAR-NKT cells” NCT06728189 ↗ |
| Route | Other | “infusion of CAR-NKT on day 0” NCT06728189 ↗ |
| Target | CD70 | “CD70-targeted CAR-NKT Cells Therapy” NCT06728189 ↗ |